VERTEX PHARMACEUTICALS INC / MA Foreign Currency Transaction Gain (Loss), before Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$13.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA foreign currency transaction gain (loss), before tax for fiscal 2025 was -$13.70M.
- VERTEX PHARMACEUTICALS INC / MA foreign currency transaction gain (loss), before tax for fiscal 2024 was -$27.30M.
- VERTEX PHARMACEUTICALS INC / MA foreign currency transaction gain (loss), before tax for fiscal 2023 was -$24.60M.
- VERTEX PHARMACEUTICALS INC / MA foreign currency transaction gain (loss), before tax for fiscal 2022 was -$15.10M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$13.70M 10-K · filed 2026-02-13 | |
| 2024-12-31 | -$27.30M 10-K · filed 2026-02-13 | |
| 2023-12-31 | -$24.60M 10-K · filed 2026-02-13 | |
| 2022-12-31 | -$15.10M 10-K · filed 2025-02-13 | |
| 2021-12-31 | -$13.90M 10-K · filed 2024-02-15 | |
| 2020-12-31 | -$16.10M 10-K · filed 2023-02-10 | |
| 2019-12-31 | -$5.20M 10-K · filed 2022-02-09 | |
| 2018-12-31 | -$1.10M 10-K · filed 2021-02-11 | |
| 2017-12-31 | -$5.50M 10-K · filed 2020-02-13 | $5.50M 10-K · filed 2018-02-15 |
| 2016-12-31 | $4.00M 10-K · filed 2019-02-13 | |
| 2015-12-31 | -$6.80M 10-K · filed 2018-02-15 | |
| 2014-12-31 | -$6.40M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $5.10M 10-K · filed 2016-02-16 | |
| 2012-12-31 | -$400.00K 10-K · filed 2015-02-13 | $400.00K 10-K · filed 2013-03-01 |
| 2011-12-31 | $700.00K 10-K · filed 2014-02-11 | -$700.00K 10-K · filed 2013-03-01 |
| 2010-12-31 | -$100.00K 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |